Twist Bioscience Corporation (NASDAQ:TWST) Receives $46.50 Consensus Target Price from Analysts

Twist Bioscience Corporation (NASDAQ:TWST) has received a consensus recommendation of “Moderate Buy” from the nine research firms that are presently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating and seven have assigned a buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $46.50.

A number of equities research analysts have recently weighed in on TWST shares. Robert W. Baird set a $50.00 price target on Twist Bioscience in a research note on Tuesday, February 3rd. TD Cowen restated a “buy” rating on shares of Twist Bioscience in a research note on Thursday, January 8th. Guggenheim boosted their price target on Twist Bioscience from $50.00 to $55.00 and gave the stock a “buy” rating in a research note on Monday, March 30th. Evercore boosted their price target on Twist Bioscience from $42.00 to $52.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 3rd. Finally, Barclays boosted their price target on Twist Bioscience from $39.00 to $50.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 3rd.

Twist Bioscience Price Performance

Shares of TWST stock opened at $50.12 on Friday. Twist Bioscience has a fifty-two week low of $23.30 and a fifty-two week high of $57.88. The firm has a market capitalization of $3.07 billion, a price-to-earnings ratio of -39.16 and a beta of 2.20. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.37 and a current ratio of 3.78. The stock’s 50-day simple moving average is $47.31 and its 200-day simple moving average is $37.75.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings results on Monday, February 2nd. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.02). Twist Bioscience had a negative return on equity of 27.16% and a negative net margin of 19.56%.The business had revenue of $103.70 million for the quarter, compared to analysts’ expectations of $100.32 million. The business’s revenue for the quarter was up 16.9% compared to the same quarter last year. As a group, equities analysts forecast that Twist Bioscience will post -2.12 earnings per share for the current fiscal year.

Insider Transactions at Twist Bioscience

In related news, CEO Emily M. Leproust sold 2,423 shares of the company’s stock in a transaction that occurred on Friday, March 6th. The stock was sold at an average price of $46.43, for a total value of $112,499.89. Following the sale, the chief executive officer owned 860,629 shares in the company, valued at $39,959,004.47. This represents a 0.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Adam Laponis sold 7,000 shares of the company’s stock in a transaction that occurred on Thursday, February 12th. The shares were sold at an average price of $50.00, for a total value of $350,000.00. Following the completion of the sale, the chief financial officer owned 130,031 shares in the company, valued at approximately $6,501,550. This represents a 5.11% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 49,190 shares of company stock valued at $2,285,695 over the last quarter. Company insiders own 3.08% of the company’s stock.

Institutional Investors Weigh In On Twist Bioscience

A number of large investors have recently bought and sold shares of the company. Stifel Financial Corp boosted its position in Twist Bioscience by 3.6% in the fourth quarter. Stifel Financial Corp now owns 7,769 shares of the company’s stock valued at $246,000 after buying an additional 271 shares during the last quarter. D.A. Davidson & CO. boosted its position in Twist Bioscience by 1.2% in the fourth quarter. D.A. Davidson & CO. now owns 25,237 shares of the company’s stock valued at $801,000 after buying an additional 305 shares during the last quarter. CWM LLC boosted its position in Twist Bioscience by 9.4% in the fourth quarter. CWM LLC now owns 4,738 shares of the company’s stock valued at $150,000 after buying an additional 407 shares during the last quarter. Smartleaf Asset Management LLC boosted its position in Twist Bioscience by 70.6% in the third quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock valued at $29,000 after buying an additional 442 shares during the last quarter. Finally, California State Teachers Retirement System boosted its position in Twist Bioscience by 0.8% in the second quarter. California State Teachers Retirement System now owns 54,187 shares of the company’s stock valued at $1,994,000 after buying an additional 442 shares during the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.